Google
SEELQ Stock Price & Analysis — Seelos Therapeutics, Inc. (Healthcare >> Biotechnology)
SEELQ FAQ
What is SEELQ's ROE?
Seelos Therapeutics, Inc. reports a Return on Equity (ROE) of -14.54%.
What is SEELQ's dividend yield?
Seelos Therapeutics, Inc. offers a dividend yield of 0.00%.
What is SEELQ's Quality Score?
Our AI rates SEELQ's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SEELQ?
Our AI Timing Score for SEELQ is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SEELQ belong to?
Seelos Therapeutics, Inc. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
SEELQ AI Analysis Summary
Our AI summary for SEELQ: Seelos Therapeutics, Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -14.54%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.00
Price
0
(0%)
Day Change
|
|
|---|
SEELQ, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | N/A |
| PBV / Sector |
N/A / 44,105.10
|
| Earning Per Share | 7.05 |
| PE / Sector |
N/A / 19.37
|
| PEG or PE/Growth / Sector |
N/A / 1.06
|
| Average 1M Daily Value |
0.002225000000
GREAT
|
| Average 1W Daily Value |
0.000000000000
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
8% |
| Registration Details |
| Analyze Date | 2026-08-06 08:00:39 |
| Symbol | SEELQ |
| Name | SEELOS THERAPEUTICS, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 0.58 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | N/A / 9,702.21 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 300 Park Avenue, New York, NY, United States, 10022
Phone: 646 293 2100
Website: https://seelostherapeutics.com
Sector: Healthcare >> Biotechnology
Description: Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap